{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:15:53Z","timestamp":1778624153619,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.hoc.2014.08.003","type":"journal-article","created":{"date-parts":[[2014,10,4]],"date-time":"2014-10-04T10:37:59Z","timestamp":1412419079000},"page":"1023-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative Disease"],"prefix":"10.1016","volume":"28","author":[{"given":"Rachel B.","family":"Salit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2014.08.003_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.003_bib2","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/asheducation-2011.1.222","article-title":"Management of myelofibrosis","volume":"2011","author":"Vannucchi","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2014.08.003_bib4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.003_bib6","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2014.08.003_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1988.tb02507.x","article-title":"A\u00a0prognostic classification of myelofibrosis with myeloid metaplasia","volume":"70","author":"Barosi","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.003_bib10","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib11","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.003_bib13","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.003_bib15","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1182\/blood-2011-04-349142","article-title":"Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis","volume":"117","author":"Deeg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib16","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","article-title":"The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib17","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","article-title":"Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients","volume":"118","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib18","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.003_bib20","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.003_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib25","unstructured":"Group EEIW. Indication and management of allogeneic stem cell transplantation in myelofibrosis: a consensus process by a EBMT\/ELN international working group. March 6, 2014."},{"key":"10.1016\/j.hoc.2014.08.003_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib28","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.003_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2014.08.003_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2008.07010.x","article-title":"Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation","volume":"141","author":"Ciurea","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib32","first-page":"13","article-title":"Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients","volume":"8","author":"Michallet","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2014.08.003_bib34","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V97.7.2180","article-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib36","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kroger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V98.3.586","article-title":"Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis","volume":"98","author":"Anderson","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00005-006-0044-9","article-title":"Hematopoietic cell transplantation for chronic myeloproliferative disorders","volume":"54","author":"Tse","year":"2006","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.hoc.2014.08.003_bib40","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood.V67.6.1693.1693","article-title":"Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation","volume":"67","author":"Rajantie","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/bmt.2009.10","article-title":"A\u00a0retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis","volume":"44","author":"Gupta","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib43","first-page":"2831","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.bmt.1704657","article-title":"Outcome of allogeneic stem cell transplantation in patients with myelofibrosis","volume":"34","author":"Ditschkowski","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib45","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3324\/haematol.2011.061168","article-title":"Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Ditschkowski","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.003_bib46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib47","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.bmt.1704075","article-title":"Stem cell transplantation for myelofibrosis: a report from two Canadian centers","volume":"32","author":"Daly","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib49","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1038\/bcj.2012.3","article-title":"How to manage the transplant question in myelofibrosis","volume":"2","author":"Ballen","year":"2012","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2014.08.003_bib50","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3324\/haematol.12828","article-title":"Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"93","author":"Patriarca","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.003_bib51","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","article-title":"Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes","volume":"19","author":"Rezvani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib52","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib53","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib54","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2005.05373.x","article-title":"Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis","volume":"128","author":"Kroger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08582.x","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age","volume":"153","author":"Samuelson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2006.06302.x","article-title":"Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens","volume":"135","author":"Merup","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.003_bib58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bmt.2011.91","article-title":"The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries","volume":"47","author":"Abelsson","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib59","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bmt.2010.14","article-title":"The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study","volume":"45","author":"Stewart","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.003_bib60","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2009-11-252601","article-title":"Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis","volume":"116","author":"Takagi","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2014.08.003_bib61","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood.V122.21.301.301","article-title":"Outcomes after unrelated cord blood transplantation for adults with primary or secondary myelofibrosis: a retrospective study on behalf of Eurocord and chronic malignancy working party-EBMT","volume":"122","author":"Robin","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2014.08.003_bib62","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.003_bib63","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.003_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib","volume":"49","author":"Jaekel","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.003_bib65","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/leu.2014.86","article-title":"JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET\/PV myelofibrosis","volume":"28","author":"Stubig","year":"2014","journal-title":"Leukemia"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:01:06Z","timestamp":1760184066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858814001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0889858814001038"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2014.08.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2014.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}